In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL

the ONA take:

Pazopanib improved progression-free survival but did not impact health-related quality of life in patients with soft tissue sarcoma who experienced disease progression during or after prior chemotherapy, according to a new study published in the journal Cancer.

The global, double-blind, phase III PALETTE trial found that pazopanib 800 mg as second-line or later treatment improved median progression-free survival by 3 months compared with placebo in patients with advanced soft tissue sarcoma. Researchers also found that the most common adverse events associated with pazopanib treatment were diarrhea, fatigue, hypertension, nausea, and weight loss.

Researchers also conducted an exploratory analysis to evaluate the impact of pazopanib treatment on health-related quality of life. Patients were assessed using the 30-item core EORTC Quality-of-Life Questionnaire at baseline and at 4, 8, and 12 weeks of treatment.

Results showed that there was no statistically significant different in global health status between pazopanib and placebo; however, those receiving pazopanib reported significantly worse scores for diarrhea, fatigue, loss of appetite, and nausea/vomiting than those who received placebo. Researchers found that health-related quality of life score tended to decrease over time in both treatment groups.

Pazopanib (Votrient) was initially approved by the U.S. Food and Drug Administration in 2009 for the treatment of patients with advanced renal cell carcinoma.

In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL
Pazopanib improved PFS but did not impact HRQoL in patients with soft tissue sarcoma who experienced disease progression during or after prior chemo.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs